Standards establish the baseline
NRC/NASEM references guide nutritional development; they do not prove product performance.
Evidence & Standards
A source library with claim boundaries built in.
Trail Range separates nutritional standards, regulatory guidance, systematic reviews, controlled studies and finished-product substantiation.
Evidence policy
How a source is allowed to be used.
Every record in the register was retrieved and read before it was added, and each one states its own limits.
Studies have narrow scope
Species, ingredient, dose, formulation, population and outcome must match the proposed claim.
Finished products need finished evidence
A marketed claim requires the actual formula, serving, intended use, safety review and substantiation record.
Public language standard
Trail Range uses “science-informed product development.” “Science-backed product” is reserved for a finished product with an approved claim-to-evidence file.
Source register
62 sources, grouped by domain.
Every record states what it supports and, separately, what it cannot establish. The second line is the one that governs what may be said in public.
Foundational standards
The nutrient standards everything else is measured against.
Consensus requirement references set the quantitative floor and ceiling for formulation work. They describe nutrients, not products, and none of them substantiates a finished formula.
6sources
6 sources · 2021 back to 2006
Nutrient Requirements of Dairy Cattle: Eighth Revised Edition
National Academies of Sciences, Engineering, and Medicine
Scope. Requirements for preweaning, growing, reproducing and lactating dairy cattle across energy, protein and amino acids, minerals, vitamins and water.
Supports. Formulation targets for early-life calf products and the amino-acid-based protein framework expected in a technical dossier.
Does not establish. Does not establish efficacy, safety or economic return for any additive or supplement; requirement estimates are population-level, not herd-specific.
Primary source ↗Effect of l-theanine tablets in reducing stress-related emotional signs in cats: an open-label field study
Irish Veterinary Journal
Scope. Feline study, included as the fairest available off-species check on L-theanine positioning. Open-label field study in 33 cats with stress-related emotional signs, scoring 20 behavioural parameters over 30 days. The only L-theanine companion-animal study indexed in PubMed.
Supports. Reports that all 20 median parameter scores fell significantly by day 30, with most cats improving within two weeks.
Does not establish. Does not transfer to dogs, and does not establish an ingredient effect in any species: it is open-label with no placebo or control arm, so within-subject improvement cannot be separated from regression to the mean or caregiver expectation.
Primary source ↗The effects of magnesium supplementation on subjective anxiety and stress — a systematic review
Nutrients / University of Leeds
Scope. Human evidence, included as the fairest available check on magnesium positioning. Systematic search across Medline, PsycINFO, Embase, CINAHL and Cochrane plus grey literature, including 18 human intervention studies.
Supports. The complete magnesium-anxiety evidence base in one place, and the honest ceiling on it: benefit was found in only 4 of 8 anxious samples and 4 of 7 premenstrual samples.
Does not establish. Does not establish efficacy in any species — the authors conclude the quality of the existing evidence is poor; every study recruited humans already vulnerable to anxiety, no study used a validated subjective stress measure, and many combined magnesium with other actives.
Primary source ↗Nutrient Requirements of Beef Cattle: Eighth Revised Edition
National Academies of Sciences, Engineering, and Medicine
Scope. Energy, protein, mineral and vitamin requirements for beef cattle, with feed composition tables covering grazed forages.
Supports. The numerical basis for target nutrient concentrations and intake assumptions in mineral, protein and energy supplements.
Does not establish. Does not establish that any commercial product meets those requirements in the field, and does not predict production responses to supplementation above requirement.
Primary source ↗Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: a randomized clinical trial
Phytomedicine / University of Pennsylvania
Scope. Human study, included as the fairest available check on chamomile positioning. Twelve weeks open-label chamomile extract at 1,500 mg/day followed by 26 weeks double-blind placebo-substitution in 179 enrolled adults, of whom 93 responders were randomised.
Supports. The most rigorous test chamomile has against an anxiety endpoint in any species, and the reason the ingredient has a scientific reputation at all.
Does not establish. Does not establish efficacy even in humans — the primary endpoint, time to relapse, was not significant (HR 0.52, 95% CI 0.20–1.33, P = 0.16); it is a human trial in diagnosed generalized anxiety disorder at a standardised oral extract dose, and nothing in it transfers to dogs.
Primary source ↗Nutrient Requirements of Dogs and Cats
National Research Council / National Academies Press
Scope. Consensus requirements, adequate intakes and recommended allowances for every essential nutrient in dogs and cats, across life stages.
Supports. The quantitative floor and ceiling for formulating canine diets and complementary products.
Does not establish. Does not establish requirements, doses or efficacy for probiotics, prebiotics, postbiotics, glucosamine, collagen or any other non-essential ingredient.
Primary source ↗Canine
Dog-specific reviews, trials and clinical guidance.
Digestive, mobility, skin-and-coat and behaviour research, read at the level the studies actually support — species, ingredient, dose, population and outcome all have to match before anything reaches a claim.
27sources
27 sources · 2026 back to 2000
ACVIM consensus statement and systematic review on chronic inflammatory enteropathy in dogs
American College of Veterinary Internal Medicine
Scope. Graded diagnostic and treatment evidence for canine chronic inflammatory enteropathy, including dietary trials, hydrolysed and fibre-enriched diets, and biotics.
Supports. Confirms diet as the evidence-led first-line intervention and fibre-enriched formulation as a legitimate development target.
Does not establish. Does not support standalone biotic claims — the panel assigns probiotics only a weak recommendation, and it addresses diagnosed disease rather than healthy-dog maintenance.
Primary source ↗Cutaneous food allergy in animals
MSD Veterinary Manual
Scope. Professional reference on diagnosis and management of cutaneous adverse food reactions, including diagnostic test performance and elimination-trial protocol.
Supports. Establishes why allergy language cannot appear on a commercial food: diagnosis requires a veterinarian-supervised elimination trial of at least ten weeks with controlled rechallenge.
Does not establish. Does not support any nutritional product as a diagnostic or therapeutic instrument, and notes serological, salivary, intradermal and hair testing do not give reliably accurate results.
Primary source ↗Behavior problems of dogs
MSD Veterinary Manual
Scope. Professional reference on canine fear, anxiety, separation anxiety and noise aversion — diagnosis, medical rule-outs, behaviour modification and pharmacotherapy.
Supports. Establishes why calm language is a regulatory hazard rather than a marketing choice: canine anxiety is a diagnosable clinical disorder requiring medical rule-outs, and fluoxetine and clomipramine are FDA-approved drugs for canine separation anxiety — an approved-drug indication a food cannot claim into.
Does not establish. Does not endorse any nutritional product; it states that evidence of the effectiveness of natural products in dogs is somewhat limited and positions them as adjunctive to behaviour modification, never as treatment.
Primary source ↗Treats containing cannabidiol, L-tryptophan and alpha-casozepine have a mild stress-reducing effect in dogs
Frontiers in Veterinary Science
Scope. Blinded cross-over study in 54 dogs given a single dose two hours before a validated 10-minute car-travel stress paradigm, with plasma CBD, serum cortisol, heart rate variability and behaviour measured.
Supports. The largest and best-designed canine trial containing either L-tryptophan or alpha-casozepine: the 2 mg/kg CBD-plus-blend arm produced a significantly smaller cortisol rise than placebo (p = 0.016).
Does not establish. Does not attribute any effect to L-tryptophan or alpha-casozepine — both were given only inside a blend with CBD and never tested alone, and no other outcome reached significance.
Primary source ↗In adult dogs is supplementary tryptophan in the diet effective in reducing signs of anxiety?
Veterinary Evidence / RCVS Knowledge
Scope. Structured appraisal of controlled trials of dietary tryptophan for signs of anxiety in adult dogs, with formal strength-of-evidence grading.
Supports. Supports at most an adjunctive role alongside behavioural management, based on two appropriately designed low-risk-of-bias studies.
Does not establish. Does not support tryptophan as a standalone intervention — the authors conclude it is not enough as a sole treatment, and results were inconsistent between the two studies.
Primary source ↗Effectiveness of glucosamine and chondroitin sulfate, marine-based fatty acid compounds, and carprofen in dogs with hip osteoarthritis
Frontiers in Veterinary Science
Scope. Six-week block-randomised, double-blinded, placebo-controlled trial in 75 owned dogs measured against force-plate peak vertical force.
Supports. Objective gait evidence that marine lipid extracts can shift weight-bearing, and that glucosamine/chondroitin at 30 mg/kg/day performed similarly to placebo.
Does not establish. Does not extend beyond six weeks, found no significant between-group difference on subjective scoring, and was supported by a supplement manufacturer.
Primary source ↗Effects of dietary camelina, flaxseed and canola oil supplementation on inflammatory markers, transepidermal water loss and coat quality in healthy adult dogs
Frontiers in Veterinary Science
Scope. Randomised complete block design in 30 healthy client-owned dogs comparing three plant oils over 16 weeks.
Supports. Supports the honest position that oil supplementation is associated with graded improvement in coat softness, shine and colour intensity from baseline.
Does not establish. Does not establish superiority of any one oil — outcomes did not differ between groups, there was no untreated control, and no change in transepidermal water loss was detected, which argues against a barrier-function claim.
Primary source ↗Therapy and prevention of noise fears in dogs — a review of the current evidence for practitioners
Animals / University of Bern
Scope. Review of the evidence for every major intervention class in canine noise fear — environmental management, counterconditioning, desensitisation, anxiolytic medication, nutraceuticals, herbals, pheromones and homeopathy.
Supports. The single best summary of where calm-behaviour nutrition actually sits: it places nutraceuticals below medication and below training, and identifies caregiver placebo as the dominant explanation for reported effects.
Does not establish. Does not test any ingredient itself, and states the opposite of a calm claim — that the effect of the majority of nutraceuticals in use does not exceed that of a caregiver placebo effect, and that most will likely provide insufficient relief as monotherapy for noise fears.
Primary source ↗Dietary strategies for relieving stress in pet dogs and cats
Antioxidants (Basel)
Scope. Tabulated review of dietary compounds studied against stress endpoints in dogs and cats, listing species, dose and reported outcome for each — including L-theanine, alpha-casozepine and L-tryptophan.
Supports. Establishes the boundary of the field by enumeration: it is the most complete catalogue of what has actually been fed to dogs for stress, with doses attached.
Does not establish. Does not appraise risk of bias, dose-response or study quality, and contains no entry for magnesium or chamomile in dogs — the absence in a review built to find such studies is itself the finding.
Primary source ↗Systematic review and meta-analysis of enriched therapeutic diets and nutraceuticals in canine and feline osteoarthritis
Université de Montréal / International Journal of Molecular Sciences
Scope. Screened 1,578 publications and pooled 72 trials across nine categories of natural health compound in dogs and cats with osteoarthritis.
Supports. Ranks long-chain omega-3 fatty acids as the lead functional ingredient by effect size, and de-prioritises glucosamine–chondroitin.
Does not establish. Does not validate any commercial formulation; the authors flag subjective outcome tools, groups often under ten animals, and wide variation in dose and duration.
Primary source ↗Therapeutic effect of EPA/DHA supplementation in neoplastic and non-neoplastic companion animal diseases: a systematic review
In Vivo
Scope. Systematic review of randomised controlled EPA/DHA studies in dogs and cats with Cochrane RoB2 risk-of-bias assessment; 23 studies included.
Supports. Identifies benefit in canine allergic dermatitis and haircoat disorder among included trials — the strongest single citation for an EPA/DHA coat rationale.
Does not establish. Does not establish effect size, dose or duration for a healthy-dog maintenance product; benefit was found in diseased animals under veterinary management.
Primary source ↗Investigating the effects of incremental conditioning and supplemental dietary tryptophan on the voluntary activity and behaviour of mid-distance training sled dogs
PLOS ONE / University of Guelph
Scope. Sixteen client-owned Siberian Huskies blocked for age, bodyweight and sex, randomly allocated to control or tryptophan supplementation at a tryptophan:large-neutral-amino-acid ratio of 0.075:1 across a 12-week incremental training regimen.
Supports. The only canine tryptophan trial in healthy working dogs rather than behaviourally affected patients, and it supplies a defensible dosing target expressed as a Trp:LNAA ratio rather than a raw milligram figure.
Does not establish. Does not demonstrate a calming effect — treatment had no effect on activity levels, and with 16 dogs of one breed under training it cannot separate supplementation from conditioning.
Primary source ↗Clinical effect of probiotics in prevention or treatment of gastrointestinal disease in dogs: a systematic review
Journal of Veterinary Internal Medicine
Scope. Screened 165 studies, including 17 in vivo canine trials, grading design quality and risk of bias; stool consistency was the most reported outcome.
Supports. Establishes stool consistency as the practical primary outcome for canine digestive research and the need for strain-level data.
Does not establish. Does not support a general probiotic efficacy claim in dogs — the authors found a very limited and possibly clinically unimportant effect, with moderate-to-high risk of bias throughout.
Primary source ↗Effects on nutrient utilization and stool quality of Beagle dogs fed diets with beet pulp, cellulose and Miscanthus grass
Journal of Animal Science / Kansas State University
Scope. Replicated Latin square in 12 Beagles comparing three fibre sources at 10% inclusion with total faecal collection.
Supports. Quantifies the fibre trade-off directly: beet pulp raised dry matter and total dietary fibre digestibility and lowered wet faecal output versus cellulose and Miscanthus.
Does not establish. Does not demonstrate a clinical gut-health benefit; beet pulp also lowered crude protein digestibility and produced softer stools, in 12 healthy laboratory dogs at one inclusion level.
Primary source ↗Critically appraised topic on adverse food reactions: discrepancies between ingredients and labeling in commercial pet foods
BMC Veterinary Research
Scope. Appraisal of 18 studies using PCR, ELISA and mass spectrometry to compare declared against actual protein content in commercial pet foods.
Supports. Directly justifies supply-chain control and analytical ingredient verification: a median 45% of foods tested contained unlisted ingredients.
Does not establish. Does not establish that a contaminating ingredient provokes a clinical reaction — no challenge studies were performed — so it cannot support a claim that a verified product prevents reactions.
Primary source ↗ISAPP consensus statement on the definition and scope of prebiotics
International Scientific Association for Probiotics and Prebiotics
Scope. Expert panel defining a prebiotic as a substrate selectively utilised by host microorganisms conferring a health benefit.
Supports. Provides the two-part test a candidate fibre must meet — demonstrated selective utilisation plus a demonstrated host benefit.
Does not establish. Does not certify any specific ingredient as a prebiotic in dogs; fermentability data alone does not satisfy the definition without a documented benefit in the target species.
Primary source ↗Evaluation of three hydration strategies in detection dogs working in a hot environment
Frontiers in Veterinary Science
Scope. Randomised cross-over field study in seven working dogs comparing plain water, flavoured oral electrolyte solution and subcutaneous fluids.
Supports. Shows flavoured electrolyte solution more than doubled voluntary fluid intake versus water, making palatability-driven intake a legitimate design objective.
Does not establish. Does not demonstrate any performance or thermoregulatory benefit — no effect was detected on body temperature or search performance.
Primary source ↗Is alpha-casozepine efficacious at reducing anxiety in dogs?
Veterinary Evidence / RCVS Knowledge
Scope. Structured PICO appraisal of published evidence for alpha-casozepine as an anxiolytic in dogs, short-term and longer-term.
Supports. Supports only a cautious, heavily qualified position, and is the correct disclosure to make wherever the ingredient appears.
Does not establish. Does not support situational use at all — the appraisal finds no evidence of effect when given shortly before a stressor — and rates the longer-term evidence limited, weak and at high risk of bias.
Primary source ↗Analysis of serum magnesium ions in dogs exposed to external stress: a pilot study
Open Veterinary Journal
Scope. Observational pilot in guide-dog candidates and healthy adult dogs measuring serum Mg2+ across seasons, training stage and a treadmill forced-exercise challenge, 4–14 dogs per group.
Supports. The only canine study in the literature linking magnesium to stress at all: serum Mg2+ fell in winter, was markedly lower in novice than advanced trainees, and dropped significantly after forced treadmill exercise.
Does not establish. Does not test supplementation and measures no behavioural or anxiety outcome; its closing recommendation that supplementation should be considered is author speculation with no interventional data behind it and must not be cited as support for a calm claim.
Primary source ↗Treatment of canine atopic dermatitis: 2015 updated guidelines from ICADA
International Committee on Allergic Diseases of Animals / BMC Veterinary Research
Scope. International expert guidelines on managing acute flares and chronic atopic dermatitis in dogs, with graded strength-of-recommendation statements.
Supports. Legitimises a supportive, adjunctive nutritional role alongside flare-factor avoidance and coat hygiene.
Does not establish. Does not support essential fatty acids as monotherapy — the guidelines state the limited improvement expected makes EFA supplementation unsuitable as sole treatment of canine atopic dermatitis.
Primary source ↗An open-label prospective study of the use of l-theanine (Anxitane) in storm-sensitive client-owned dogs
Journal of Veterinary Behavior
Scope. Open-label prospective study in 26 client-owned storm-sensitive dogs, measuring owner-reported global anxiety score and time to return to baseline after a storm. The only full-length canine L-theanine paper in client-owned dogs.
Supports. Reports a reduction in owner-scored anxiety and faster return to baseline — the entire real-world basis for canine L-theanine positioning.
Does not establish. Does not control for placebo at all — it is open-label with no blinded comparator, outcomes are owner-reported, and 8 of 26 dogs dropped out prematurely, which the 2023 noise-fear review flags as creating potential bias in the remaining analysed subjects.
Primary source ↗ISAPP consensus statement on the scope and appropriate use of the term probiotic
International Scientific Association for Probiotics and Prebiotics
Scope. Expert panel defining a probiotic as live microorganisms which, in adequate amounts, confer a health benefit on the host.
Supports. Sets the ingredient-qualification gate: a defined, characterised strain with its own safety and efficacy evidence at a specified viable dose.
Does not establish. Does not establish efficacy for any strain, and holds explicitly that effects are strain-specific and cannot be extrapolated between strains.
Primary source ↗Nutrition for working and service dogs
Veterinary Clinics of North America: Small Animal Practice
Scope. Review of nutritional physiology across canine work types, covering dietary fat, glycogen repletion, protein and ageing working dogs.
Supports. The macronutrient design logic for work-type-specific formulation — higher fat for endurance, balanced macronutrients for sprint work, post-exercise carbohydrate for repeated efforts.
Does not establish. Does not rest on trial evidence for all work types; the authors state that studies for agility, field-trial and detection dogs are rare, so those recommendations are extrapolated.
Primary source ↗The effect of weight loss on lameness in obese dogs with osteoarthritis
Veterinary Research Communications
Scope. Open prospective 16-week trial in 14 obese dogs with radiographically confirmed osteoarthritis, assessed by rating scales and kinetic gait analysis.
Supports. Quantifies the threshold at which lameness change becomes detectable — subjectively from about 6.1% body-weight loss, on gait analysis from about 8.9%.
Does not establish. Does not include a control group or blinding; with 14 dogs it cannot separate weight loss from diet composition or increased owner attention.
Primary source ↗Effects of alpha-casozepine (Zylkene) versus selegiline hydrochloride (Selgian, Anipryl) on anxiety disorders in dogs
Journal of Veterinary Behavior
Scope. Comparison of alpha-casozepine against the licensed drug selegiline hydrochloride in dogs with diagnosed anxiety disorders. The principal canine trial underlying the ingredient's market position.
Supports. The one canine study positioning alpha-casozepine against an active veterinary comparator rather than nothing.
Does not establish. Does not include a placebo arm — an active-comparator design cannot separate ingredient effect from natural remission, regression to the mean or caregiver placebo, and the 2017 structured appraisal rates this body of evidence limited, weak and at high risk of bias.
Primary source ↗Lifelong diet restriction and radiographic evidence of osteoarthritis of the hip joint in dogs
Journal of the American Veterinary Medical Association
Scope. Lifetime paired-littermate study in 48 Labrador Retrievers fed either ad libitum or 25% less of the same diet from eight weeks of age.
Supports. Establishes lifetime energy control as the best-evidenced nutritional lever on joint outcomes — median age at first radiographic osteoarthritis 12 years restricted versus 6 years control.
Does not establish. Does not test any supplement or functional ingredient, uses radiographic rather than pain endpoints, and studied one breed in a controlled colony.
Primary source ↗Effect of dietary protein content and tryptophan supplementation on dominance aggression, territorial aggression, and hyperactivity in dogs
Journal of the American Veterinary Medical Association
Scope. Prospective randomised crossover in which dogs received four diets — low protein (~18%) and high protein (~30%), each with and without tryptophan — for one week each, with 11 dogs per behavioural category.
Supports. The foundational canine tryptophan trial, and the source of the still-current formulation insight that tryptophan and dietary protein level interact: territorial aggression scores were significantly lower on tryptophan-supplemented low-protein diets.
Does not establish. Does not establish a general calming effect — outcomes were owner-scored on non-validated sheets, each arm ran only one week in 11 dogs, and the result is inseparable from dietary protein level.
Primary source ↗Livestock
Neonatal and production evidence for cattle systems.
Passive-transfer benchmarks, colostrum-program research, hydration trials and grazing-nutrition guidance. Several of these sources are here because of what they failed to show.
16sources
16 sources · 2026 back to 2007
Electrolyte supplementation for gestating beef cows under heat stress: performance, thermotolerance and physiological responses
Translational Animal Science
Scope. Controlled trial in 54 fall-calving cows comparing plain water against electrolyte-supplemented water for roughly 90 days prepartum under heat stress.
Supports. Honest evidence that a commercial electrolyte can shift hydration and acid-base markers in heat-stressed cows.
Does not establish. Does not establish any production or thermotolerance benefit — body weight, condition score, calf birth weight, respiration rate and body temperature were all unaffected.
Primary source ↗Invited review: probiotic approaches to improving dairy production
Journal of Dairy Science
Scope. Critical review of direct-fed microbials in dairy cattle and calves, covering microbial ecology, host immune interaction and production outcomes.
Supports. Establishes that direct-fed microbial effects are strain-, stage- and farm-specific, justifying defined-strain development over generic positioning.
Does not establish. Does not support generalised efficacy claims — the authors report efficacy has been highly variable and that all direct-fed microbials are not created equal.
Primary source ↗Body condition scoring beef cattle (Publication P2508)
Mississippi State University Extension Service
Scope. Guide to the 1–9 body condition scoring scale, target scores by class and the nutrient density required to change condition.
Supports. Establishes body condition score as the practical, low-cost lever a nutrition program should be designed and measured against.
Does not establish. Does not establish that any specific supplement changes body condition score, and its reproductive statements are directional rather than quantified.
Primary source ↗Trace mineral nutrition of grazing beef cattle
Animals
Scope. Review of trace mineral status, antagonism and supplementation strategy in forage-based beef systems.
Supports. Justifies region-specific formulation and antagonist-adjusted inclusion rates; documents that free-choice intake varies enormously between individuals.
Does not establish. Does not establish that organic trace mineral sources outperform inorganic ones in ruminants — the authors describe that advantage as less clear and highly variable.
Primary source ↗Consensus recommendations on calf- and herd-level passive immunity in dairy calves in the United States
Journal of Dairy Science
Scope. Replaces the binary pass/fail passive-transfer standard with four serum IgG categories and corresponding herd-level distribution goals.
Supports. The current US reference framework against which a colostrum program and any product used within it should be benchmarked and monitored.
Does not establish. Does not establish that any product or protocol moves calves between categories; it defines measurement thresholds and herd targets, not interventions.
Primary source ↗Comparison of oral, intravenous and subcutaneous fluid therapy for resuscitation of calves with diarrhea
Journal of Dairy Science
Scope. Randomised trial in calves with induced diarrhoea and dehydration comparing oral electrolyte solution against intravenous and subcutaneous routes.
Supports. Substantiates a properly formulated oral electrolyte as first-line rehydration for calves that retain a functional gut.
Does not establish. Does not reflect naturally occurring disease — diarrhoea was experimentally induced, acidemia was relatively mild, and treatment arms were not composition-matched.
Primary source ↗Protein and energy supplementation for beef cattle grazing rangelands (Circular 564)
New Mexico State University Cooperative Extension Service
Scope. Synthesis of the protein-versus-energy supplementation decision on dormant and low-quality rangeland forage, including delivery frequency.
Supports. Justifies protein-first supplement design on dormant forage and supports infrequent delivery with minimal performance penalty.
Does not establish. Does not support high-starch energy supplementation as a substitute, since such supplements suppress forage intake and digestion, and does not establish transfer outside dormant semi-arid rangeland.
Primary source ↗Serum protein electrophoretic pattern in neonatal calves treated with clinoptilolite
Molecules
Scope. 18 calves in three groups — colostrum alone, colostrum plus 0.5% clinoptilolite, colostrum plus 2% — dosed within two hours of birth and again at 12 and 24 hours.
Supports. The only head-to-head dose comparison in the colostrum window: at 30 hours the 0.5% group showed γ-globulin markedly above control, and the authors conclude the lower dose was the more effective of the two.
Does not establish. Does not measure IgG directly (γ-globulin is a proxy), uses six calves per arm, records no clinical endpoint, and shows the higher 2% dose performing worse than 0.5% — the effect is dose-critical, not linear.
Primary source ↗Failure of passive immune transfer in calves: a meta-analysis on the consequences and assessment of the economic impact
PLOS ONE
Scope. Meta-analysis of 68 published models quantifying adjusted risk of mortality, respiratory disease, diarrhoea and overall morbidity associated with failure of passive transfer.
Supports. Quantifies the health burden attached to failure of passive transfer, justifying it as a high-value development target.
Does not establish. Does not demonstrate that raising serum IgG by any given intervention delivers a proportional reduction in disease — the estimates are associational, with substantial heterogeneity.
Primary source ↗Diagnostic accuracy of refractometry for assessing bovine colostrum quality: a systematic review and meta-analysis
Journal of Dairy Science
Scope. Meta-analysis of 11 studies and 4,251 colostrum samples evaluating Brix refractometry against an IgG standard at different cutoffs.
Supports. Validates on-farm Brix as a screening input for colostrum quality decisions and quantifies the confidence each cutoff carries.
Does not establish. Does not establish that Brix predicts a calf's achieved serum IgG — it measures agreement with colostral IgG concentration only.
Primary source ↗Invited review: transitioning from milk to solid feed in dairy heifers
Journal of Dairy Science
Scope. Review of rumen ecosystem development, fermentation, papillae growth and rumination behaviour across the milk-to-solid-feed transition.
Supports. Informs starter formulation direction — specifically the balance between physically effective fibre and readily degradable carbohydrate.
Does not establish. Does not provide a validated numeric formulation specification, and as a narrative review applies no systematic risk-of-bias appraisal.
Primary source ↗Effect of feeding maternal colostrum or plasma-derived or colostrum-derived colostrum replacer on passive transfer, health and performance of preweaning heifer calves
Journal of Dairy Science
Scope. Three-arm trial comparing maternal colostrum against plasma-derived and colostrum-derived replacers, measuring apparent efficiency of absorption and passive-transfer adequacy.
Supports. Establishes that IgG source and absorption efficiency — not IgG mass alone — drive achieved serum IgG, a core formulation consideration.
Does not establish. Does not establish an upper bound on replacer performance, as it tested a single dose of each replacer rather than dose-matched IgG.
Primary source ↗Meta-analysis of the influence of Saccharomyces cerevisiae supplementation on ruminal parameters and milk production of ruminants
Journal of Dairy Science
Scope. Quantitative meta-analysis across 110 papers, 157 experiments and 376 treatments evaluating live yeast in ruminants.
Supports. Supplies pooled, citable effect sizes for live yeast on rumen pH, volatile fatty acids, dry matter intake and milk yield.
Does not establish. Does not establish that these small average effects are commercially meaningful or that they generalise to a specific strain, dose or forage-based grazing diet.
Primary source ↗Apparent efficiency of immunoglobulin absorption in newborn calves orally treated with zeolite
Acta Veterinaria
Scope. 60 Holstein calves in four groups, fed colostrum at two volumes with or without a 25% clinoptilolite suspension, measuring serum IgG and apparent efficiency of absorption.
Supports. The largest trial addressing clinoptilolite and colostral immunoglobulin directly: serum IgG at six hours was significantly higher with zeolite at the lower colostrum volume, and apparent efficiency of absorption was highest in that group — the mineral enhanced rather than impaired absorption.
Does not establish. Does not establish a mechanism, was not blinded, records no clinical outcomes such as morbidity or scours, and comes from a single research group.
Primary source ↗Clinical observations, biochemical data and postmortem findings in young dairy calves fed zeolite clinoptilolite with milk replacer
American Journal of Veterinary Research
Scope. 26 Holstein calves fed milk replacer with 0%, 0.5% or 2% clinoptilolite twice daily for 28 days, all necropsied.
Supports. The best tolerance dataset in neonatal calves — no gross lesions attributable to treatment at necropsy, and no adverse haematology or biochemistry.
Does not establish. Does not show any benefit; it was designed as a safety study, found no difference in bodyweight or average daily gain, and reported an unexplained increase in jejunal mucosal eosinophils in treated calves.
Primary source ↗Passive transfer of immunoglobulin G and preweaning health in Holstein calves fed a commercial colostrum replacer
Journal of Dairy Science
Scope. Trial comparing maternal colostrum against a commercial colostrum replacer regimen, measuring 24-hour serum IgG and passive-transfer adequacy.
Supports. Demonstrates directly that a marketed colostrum replacer can fail to deliver adequate passive transfer, establishing why product-specific validation is mandatory.
Does not establish. Does not generalise to all replacers — the result characterises one product and dosing regimen, not the category.
Primary source ↗Regulatory framework
The rules that cap what any of this may be used to say.
The food/drug line, animal-food labeling, feed-additive authorisation, advertising substantiation and biologics licensing. This is the layer that turns a research finding into permitted — or prohibited — language.
13sources
13 sources · 2026 back to 1938
Commission Implementing Regulation (EU) 2026/167 renewing the authorisation of clinoptilolite of sedimentary origin
European Commission
Scope. The operative EU authorisation: additive 1g568, technological additives, functional groups binders and anticaking agents, all animal species, maximum 10,000 mg/kg complete feed.
Supports. Defines exactly what clinoptilolite is authorised to do and at what inclusion, together with the composition specification (≥80% clinoptilolite, ≤20% clay minerals free of fibres and quartz) and mandatory worker-protection provisions.
Does not establish. Does not authorise any zootechnical, gut-health, detoxification or mycotoxin-binding function — those are separate functional groups that clinoptilolite does not hold.
Primary source ↗Animal food labeling and pet food claims
U.S. Food and Drug Administration, Center for Veterinary Medicine
Scope. FDA's statement of animal food labeling requirements, the statutory definition of labeling, drug claims on labels, and the specific pet food claims CVM reviews.
Supports. Confirms that labeling reaches promotional brochures, testimonials and product information sheets — website copy and sell sheets are regulated speech, not just the bag.
Does not establish. Does not establish state acceptance of a label; federal labeling compliance is separate from the state registration that gates distribution.
Primary source ↗9 CFR Part 102 — licensing of veterinary biological products
USDA APHIS (Virus-Serum-Toxin Act, via eCFR)
Scope. Establishment and product licence requirements, and the data establishing purity, safety, potency and efficacy that an application must include.
Supports. Defines the pathway for any product presented as acting on immunity, and requires that all claims intended for labels and advertising be submitted as part of the application.
Does not establish. Does not apply to products marketed purely on nutrient contribution; conversely, no feed registration substitutes for a biologic licence where an immunity claim is made.
Primary source ↗Reading labels — nutritional adequacy statement formats
Association of American Feed Control Officials
Scope. Required label elements, the standardized nutritional adequacy statement formats, and what constitutes misbranding.
Supports. Gives the exact prescribed wording for each substantiation route and confirms that an incorrect adequacy statement, or a disease claim without an approved drug, is misbranding.
Does not establish. Does not carry force of law on its own — AAFCO models bind only where a state has adopted them, and AAFCO approves, certifies and endorses nothing.
Primary source ↗Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: randomized controlled trial
World Journal of Gastroenterology
Scope. Double-blind, placebo-controlled randomised trial of purified clinoptilolite-tuff over twelve weeks against a diarrhoea and symptom endpoint. Human study, included as the fairest available check on digestive positioning for this ingredient.
Supports. The most rigorous test of clinoptilolite against a diarrhoea endpoint in any species, and therefore the fairest available check on digestive-support positioning.
Does not establish. Does not support a digestive-symptom claim — the trial missed its primary endpoint, with responder rates no better than placebo; it is also a human study and does not transfer directly to any animal species.
Primary source ↗FDA's regulation of pet food
U.S. Food and Drug Administration, Center for Veterinary Medicine
Scope. How the food/drug line applies to pet food, pre-market review, food additives and GRAS, and the inapplicability of DSHEA to animals.
Supports. Confirms animal food needs no FDA pre-market review unless a food additive, but must be safe, sanitary and truthfully labeled; and that there is no dietary-supplement category for animals.
Does not establish. Does not establish that a product exempt from pre-market review is lawfully claimed — it addresses approval status, not claim substantiation.
Primary source ↗Health products compliance guidance
U.S. Federal Trade Commission
Scope. Staff guidance on advertising health-related products, replacing the 1998 dietary supplement advertising guide and broadened beyond supplements.
Supports. States that health-benefit and safety claims generally require competent and reliable scientific evidence assessed against the entire body of relevant evidence — cherry-picking favourable studies is not substantiation.
Does not establish. Does not by its terms address animal-product advertising, and its clinical-testing discussion is framed around human trials; what transfers is the standard, not a species-specific protocol.
Primary source ↗Complying with the Made in USA standard
U.S. Federal Trade Commission
Scope. The “all or virtually all” standard for unqualified US-origin claims, negligible foreign content, and the ongoing duty to review.
Supports. Defines exactly what documentation an origin claim requires before it may be made.
Does not establish. Does not permit an unqualified claim where any significant processing or ingredient is foreign-sourced; the labeling rule carries civil penalties.
Primary source ↗“Complete and balanced” pet food
U.S. Food and Drug Administration, Center for Veterinary Medicine
Scope. What a dog or cat food must do to carry complete and balanced in its nutritional adequacy statement.
Supports. Confirms the two substantiation routes — meeting an AAFCO nutrient profile, or passing a feeding trial under AAFCO procedures.
Does not establish. Does not establish nutritional adequacy for species other than dogs and cats, nor for treats or supplements, which are typically not complete and balanced.
Primary source ↗CPG Sec. 690.150 — labeling and marketing of dog and cat food diets intended to treat or prevent disease
U.S. Food and Drug Administration, Center for Veterinary Medicine
Scope. Factors FDA considers in exercising enforcement discretion over drug-approval requirements for diets marketed to treat or prevent disease.
Supports. Confirms that a disease-claim diet is legally an unapproved new animal drug, and that forbearance depends on veterinary-channel distribution with the claim absent from public-facing labeling.
Does not establish. Does not create a lawful public disease claim — it is enforcement discretion, not approval, and does not apply to nutritional supplements.
Primary source ↗IARC Monographs Volume 100C: Erionite
International Agency for Research on Cancer
Scope. Authoritative carcinogenicity evaluation of the fibrous zeolite erionite and its natural occurrence alongside other zeolite minerals.
Supports. Establishes why an explicit erionite specification is mandatory when sourcing natural zeolite: erionite is carcinogenic to humans, causes mesothelioma, and is normally associated with other zeolites including clinoptilolite.
Does not establish. Does not provide an occupational exposure limit, a validated feed-grade screening method, or any safe threshold — so a specification must state its own method and limit of detection.
Primary source ↗FTC policy statement regarding advertising substantiation
U.S. Federal Trade Commission
Scope. The prior-substantiation doctrine: advertisers must have a reasonable basis for objective claims before those claims are disseminated.
Supports. Establishes that lacking a reasonable basis is itself a deceptive act; that firms are held to reasonable implied readings; and that phrases such as “studies show” bind a firm to that advertised level of support.
Does not establish. Does not specify the evidence required for any particular claim — the reasonable basis is a sliding scale set by claim type, consequences of falsity and expert norms.
Primary source ↗21 U.S.C. § 321 — Definitions of food and drug
Federal Food, Drug, and Cosmetic Act (US Code)
Scope. Statutory definitions of food as articles used for food or drink for man or other animals, and drug as articles intended to diagnose, cure, mitigate, treat or prevent disease, or (other than food) to affect structure or function.
Supports. Establishes that the food/drug line is drawn by intended use rather than by ingredient — the same substance becomes a drug the moment a disease or non-nutritive structure-function intent is expressed.
Does not establish. Does not establish that any particular marketing sentence is lawful; it supplies the test, not its application.
Primary source ↗Ingredient assessments
Where a single ingredient needs the whole picture.
A source register answers one study at a time. An ingredient assessment collects everything published about one candidate — including the half that does not support the ingredient — before it reaches a formulation brief.